Quick Answer
Adaptimmune Therapeutics PLC reported Operating Income of -$68.76 million for fiscal year 2024.
Adaptimmune Therapeutics PLC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$68.76M | +50.8% |
| 2023 | -$139.74M | +14.8% |
| 2022 | -$163.97M | -1.1% |
| 2021 | -$162.25M | -21.6% |
| 2020 | -$133.41M | +4.6% |
| 2019 | -$139.77M | -69.7% |
| 2018 | -$82.36M | -2.1% |
| 2017 | -$80.66M | -10.8% |
| 2016 | -$72.80M | -195.4% |
| 2015 | -$24.64M | -113.9% |
| 2014 | -$11.52M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$30.29M | -144.1% | +33.8% |
| March 31, 2025 | -$45.73M | +7.2% | -211.5% |
| September 30, 2024 | -$14.68M | +68.5% | -121.4% |
| June 30, 2024 | $68.70M | +253.0% | +239.5% |
| March 31, 2024 | -$49.26M | -3074.7% | -5.6% |
| September 30, 2023 | -$46.63M | -8.5% | -3.8% |
| June 30, 2023 | -$44.91M | -2.6% | -2811.8% |
| March 31, 2023 | $1.66M | +103.3% | +103.9% |
- Adaptimmune Therapeutics PLC showed an increase of +50.8% in Operating Income compared to the prior fiscal year.
- Over the 2014–2024 period, Adaptimmune Therapeutics PLC’s operating income has declined by 496.8% (from -$11.52 million to -$68.76 million).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: